Search

Your search keyword '"Miyahara, Koji"' showing total 151 results
Start Over Author "Miyahara, Koji" Publication Type Academic Journals
151 results on '"Miyahara, Koji"'

3. Association of direct oral anticoagulant and delayed bleeding with pharmacokinetics after endoscopic submucosal dissection

Author

Murata, Masaki, Sugimoto, Mitsushige, Ueshima, Satoshi, Nagami, Yasuaki, Ominami, Masaki, Sawaya, Manabu, Nakatani, Yasuki, Furumoto, Yohei, Dohi, Osamu, Sumiyoshi, Tetsuya, Fukuzawa, Masakatsu, Tsuji, Shigetsugu, Miyahara, Koji, Takeuchi, Yoji, Suzuki, Sho, Tominaga, Naoyuki, Yagi, Nobuaki, Osawa, Satoshi, Sakata, Yasuhisa, Yamada, Takanori, Yoshizawa, Yashiro, Yamauchi, Atsushi, Yamamura, Takeshi, Orihara, Shunichiro, Miyamoto, Shin'ichi, Matsuda, Sayana, Hira, Daiki, Terada, Tomohiro, Katsura, Toshiya, Gotoda, Takuji, Fujishiro, Mitsuhiro, and Kawai, Takashi

Published
2024
Full Text
View/download PDF

4. Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy

Author

Iwamuro, Masaya, Tanaka, Takehiro, Ennishi, Daisuke, Matsueda, Kazuhiro, Yoshioka, Masao, Miyahara, Koji, Sakaguchi, Chihiro, Nishimura, Mamoru, Nagahara, Teruya, Mannami, Tomohiko, Takenaka, Ryuta, Oka, Shohei, Inoue, Masafumi, Takimoto, Hidetaka, Inaba, Tomoki, Kobayashi, Sayo, Toyokawa, Tatsuya, Tsugeno, Hirofumi, Suzuki, Seiyuu, Sawada, Sachiko, Tanaka, Shouichi, Tsuzuki, Takao, and Okada, Hiroyuki

Published
2023
Full Text
View/download PDF

7. Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study)

Author

Kanzaki, Hiromitsu, Inoue, Shuntaro, Miyake, Muneaki, Ohmori, Masayasu, Takeuchi, Yoji, Tani, Yasuhiro, Harada, Nobuyuki, Agatsuma, Nobukazu, Okada, Keijirou, Ikenouchi, Maiko, Nakatani, Yasuki, Uenoyama, Yoshito, Yamashita, Yukitaka, Ishikawa, Shigenao, Inaba, Tomoki, Miyahara, Koji, Moritou, Yuki, Nakagawa, Masahiro, Kitae, Hiroaki, Ishida, Tsugitaka, Naito, Yuji, Nishio, Akiyoshi, Shimatani, Masaaki, Kato, Ryo, Taki, Shinya, Mandai, Koichiro, Sanada, Kasumi, Nakase, Kojiro, Nebiki, Hiroko, Saito, Shunsuke, Wakatsuki, Toshiyuki, Nishimura, Naoyuki, Yamasaki, Yasushi, Uedo, Noriya, Akamatsu, Takuji, Kagawa, Tomo, Higashi, Reiji, Dohi, Osamu, Furukawa, Masanori, Takahashi, Yu, Inoue, Takuya, Tanaka, Shouichi, Takenaka, Ryuta, Iguchi, Mikitaka, Kawamura, Takuji, Tsuzuki, Takao, Yamasaki, Tomoaki, Yamashina, Takeshi, Nasu, Junichiro, Mannami, Tomohiko, Yamauchi, Atsushi, Matsueda, Kazuhiro, Aizawa, Shigeyuki, Mitsuhashi, Toshiharu, and Okada, Hiroyuki

Published
2022
Full Text
View/download PDF

11. Serum N-glycan profiles in patients with intraductal papillary mucinous neoplasms of the pancreas

Author

Akimoto, Yutaka, Nouso, Kazuhiro, Kato, Hironari, Miyahara, Koji, Dohi, Chihiro, Morimoto, Yuki, Kinugasa, Hideaki, Tomoda, Takeshi, Yamamoto, Naoki, Tsutsumi, Koichiro, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Okada, Hiroyuki, Amano, Maho, Nishimura, Shin-Ichiro, and Yamamoto, Kazuhide

Published
2015
Full Text
View/download PDF

14. Mo1228 ASSOCIATION OF DIRECT ORAL ANTICOAGULANT AND DELAYED BLEEDING WITH PHARMACOKINETICS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION

Author

Sugimoto, Mitsushige, Murata, Masaki, Nagami, Yasuaki, Ominami, Masaki, Sawaya, Manabu, Nakatani, Yasuki, Furumoto, Yohei, Dohi, Osamu, Sumiyoshi, Tetsuya, Fukuzawa, Masakatsu, Kagawa, Yasuyuki, Tsuji, Shigetsugu, Miyahara, Koji, Takeuchi, Yoji, Suzuki, Sho, Tominaga, Naoyuki, Yagi, Nobuaki, Osawa, Satoshi, Sakata, Yasuhisa, Yamada, Takanori, Yoshizawa, yashiro, Yamauchi, Atsushi, Yamamura, Takeshi, Gotoda, Takuji, Fujishiro, Mitsuhiro, and Kawai, Takashi

Published
2024
Full Text
View/download PDF

15. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion

Author

Onishi, Hideki, Nouso, Kazuhiro, Nakamura, Shinichiro, Katsui, Kuniaki, Wada, Nozomu, Morimoto, Yuki, Miyahara, Koji, Takeuchi, Yasuto, Kuwaki, Kenji, Yasunaka, Tetsuya, Miyake, Yasuhiro, Shiraha, Hidenori, Takaki, Akinobu, Kobayashi, Yoshiyuki, Sakaguchi, Kohsaku, Kanazawa, Susumu, and Yamamoto, Kazuhide

Published
2015
Full Text
View/download PDF

16. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer

Author

Nouso, Kazuhiro, Amano, Maho, Ito, Yoichi M., Miyahara, Koji, Morimoto, Yuki, Kato, Hironari, Tsutsumi, Koichiro, Tomoda, Takeshi, Yamamoto, Naoki, Nakamura, Shinichiro, Kobayashi, Sayo, Kuwaki, Kenji, Hagihara, Hiroaki, Onishi, Hideki, Miyake, Yasuhiro, Ikeda, Fusao, Shiraha, Hidenori, Takaki, Akinobu, Nakahara, Taku, Nishimura, Shin-Ichiro, and Yamamoto, Kazuhide

Published
2013
Full Text
View/download PDF

19. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis

Author

Yamasaki, Yasushi, Nouso, Kazuhiro, Miyahara, Koji, Wada, Nozomu, Dohi, Chihiro, Morimoto, Yuki, Kinugasa, Hideaki, Takeuchi, Yasuto, Yasunaka, Tetsuya, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Miyake, Yasuhiro, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Iwasaki, Yoshiaki, Amano, Maho, Nishimura, Shin-Ichiro, and Yamamoto, Kazuhide

Published
2015
Full Text
View/download PDF

23. Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma

Author

Miyahara, Koji, Nouso, Kazuhiro, Morimoto, Yuki, Takeuchi, Yasuto, Hagihara, Hiroaki, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Miyake, Yasuhiro, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Iwadou, Shouta, Kobayashi, Yoshiyuki, Takaguchi, Koichi, Takuma, Yoshitaka, Takabatake, Hiroyuki, Sakaguchi, Kohsaku, and Yamamoto, Kazuhide

Published
2014
Full Text
View/download PDF

25. Clinical utility of a serum glycome analysis in patients with colorectal cancer.

Author

Takei, Daisuke, Harada, Keita, Nouso, Kazuhiro, Miyahara, Koji, Dohi, Chihiro, Matsushita, Hiroshi, Kinugasa, Hideaki, Hiraoka, Sakiko, Nishimura, Shin‐Ichiro, and Okada, Hiroyuki

Subjects
BLOOD serum analysis, COLORECTAL cancer, RECEIVER operating characteristic curves, CANCER patients, CARCINOEMBRYONIC antigen
Abstract

Background and Aim: Serum glycans are known to be good markers for the early diagnosis and prognostic prediction in many cancers. The aims of this study were to reveal the serum glycan changes comprehensively during the process of carcinogenesis from colorectal adenoma (CRA) to colorectal cancer (CRC) and to evaluate the usefulness of the glycan profiles as clinical markers for CRC. Methods: Serum samples were obtained from 80 histologically proven CRC and 36 CRA cases. The levels of glycans in the serum were examined with a comprehensive, quantitative, high‐throughput unique glycome analysis, and their diagnostic and prognostic abilities were evaluated. Results: Among 34 stably detected glycans, nine were differentially expressed between CRC and CRA. Serum levels of hybrid type glycans were increased in patients with CRC compared with those with CRA (P < 0.001), and both hybrid‐type and multi‐antennary glycans were significantly increased in advanced cancer cases. The glycan, m/z 1914, showed the highest diagnostic value among the decreased glycans, whereas m/z 1708 showed the highest among the increased glycans. The glycan ratio m/z 1708/1914 showed a higher area under the receiver operating characteristic curve (0.889) than any other single glycan or conventional tumor marker, such as carcinoembryonic antigen (0.766, P = 0.040) and carbohydrate antigen 19‐9 (0.615, P < 0.001). High m/z 1708/1914 was also correlated with an advanced cancer stage and short overall survival. Conclusion: Serum glycans, especially the m/z 1708/1914 ratio, were useful for the diagnosis, staging, and prognosis prediction of CRC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.

Author

Adachi, Takuya, Nouso, Kazuhiro, Miyahara, Koji, Oyama, Atsushi, Wada, Nozomu, Dohi, Chihiro, Takeuchi, Yasuto, Yasunaka, Tetsuya, Onishi, Hideki, Ikeda, Fusao, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Takabatake, Hiroyuki, Fujioka, Shin‐ichi, Kobashi, Haruhiko, Takuma, Yoshitaka, Iwadou, Shouta, Uematsu, Shuji, and Takaguchi, Koichi

Subjects
HEPATITIS B, HEPATOCYTE growth factor, HEPATITIS associated antigen, HEPATOCELLULAR carcinoma, CYTOKINES, ANGIOPOIETIN-2
Abstract

Background and Aim: Several factors, including proangiogenic cytokines, have been reported as predictive markers for the treatment effect of sorafenib in patients with hepatocellular carcinoma (HCC); however, most of them were determined based on one‐time measurements before treatment. Methods: We consecutively recruited 80 advanced HCC patients who were treated with sorafenib prospectively. Serum levels of eight proangiogenic cytokines and the appearance of adverse events were monitored periodically, and their correlations with the prognoses of the patients were evaluated. Results: Among six significant risk factors for overall survival in univariate analyses, high angiopoietin‐2 (hazard ratio, 2.06), high hepatocyte growth factor (hazard ratio, 2.08), and poor performance status before the treatment (hazard ratio, 2.48) were determined as independent risk factors. In addition, high angiopoietin‐2 at the time of progressive disease was a marker of short post‐progression survival (hazard ratio, 4.27). However, there was no significant variable that predicted short progression‐free survival except the presence of hepatitis B virus surface antigen. Conclusions: Predictions of overall survival and post‐progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin‐2, in patients with HCC treated with sorafenib. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

35. The Role of an Undifferentiated Component in Submucosal Invasion and Submucosal Invasion Depth After Endoscopic Submucosal Dissection for Early Gastric Cancer.

Author

Miyahara, Koji, Hatta, Waku, Nakagawa, Masahiro, Oyama, Tsuneo, Kawata, Noboru, Takahashi, Akiko, Yoshifuku, Yoshikazu, Hoteya, Shu, Hirano, Masaaki, Esaki, Mitsuru, Matsuda, Mitsuru, Ohnita, Ken, Shimoda, Ryo, Yoshida, Motoyuki, Dohi, Osamu, Takada, Jun, Tanaka, Keiko, Yamada, Shinya, Tsuji, Tsuyotoshi, and Ito, Hirotaka

Subjects
*GASTROINTESTINAL cancer, *GASTROINTESTINAL agents, *SURGICAL excision, *HISTOPATHOLOGY, *GASTROENTEROLOGY
Abstract

Background/Aims: The role of an undifferentiated component in submucosal invasion and submucosal invasion depth (SID) for lymph node metastasis (LNM) of early gastric cancer (EGC) with deep submucosal invasion (SID ≥500 μm from the muscularis mucosa) after endoscopic submucosal dissection (ESD) has not been fully understood. This study aimed to clarify the risk factors (RFs), including these factors, for LNM in such patients. Methods: We enrolled 513 patients who underwent radical surgery after ESD for EGC with deep submucosal invasion. We evaluated RFs for LNM, including an undifferentiated component in submucosal invasion and the SID, which was subdivided into 500–999, 1,000–1,499, 1,500–1,999, and ≥2,000 µm. Results: LNM was detected in 7.6% of patients. Multivariate analysis revealed that an undifferentiated component in submucosal invasion (OR 2.22), in addition to tumor size >30 mm (OR 2.51) and lymphatic invasion (OR 3.07), were the independent RFs for LNM. However, the SID was not significantly associated with LNM. Conclusion: An undifferentiated component in submucosal invasion was one of the RFs for LNM, in contrast to SID, in patients who underwent ESD for EGC with deep submucosal invasion. This insight would be helpful in managing such patients. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

38. Potential of alpha-fetoprotein as a prognostic marker after curative radiofrequency ablation of hepatocellular carcinoma.

Author

Dohi, Chihiro, Nouso, Kazuhiro, Miyahara, Koji, Morimoto, Yuki, Wada, Nozomu, Kinugasa, Hideaki, Takeuchi, Yasuto, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, and Okada, Hiroyuki

Subjects
ALPHA fetoproteins, CATHETER ablation, TUMOR markers, CANCER relapse, LIVER cancer, PROGNOSIS
Abstract

Aim Recurrence of hepatocellular carcinoma (HCC) is observed frequently, even after curative treatments. The aim of this study is to elucidate the risk factors for recurrence of HCC after radiofrequency ablation (RFA), focusing on the carcinogenic potential of the liver assessed by α-fetoprotein (AFP). Methods We enrolled 357 consecutive patients who underwent complete ablation by RFA for primary HCC (≤3 cm, ≤3 tumors) and analyzed the correlation between 17 critical parameters, including AFP and HCC recurrence. Results Recurrence was observed in 236 patients during a mean observation period of 54.3 months. Multivariate analysis revealed that multiple tumors (risk ratio [RR] = 1.70, 95% confidence interval [CI] = 1.27-2.26, P < 0.001), high AFP (>10 ng/mL, RR = 1.45, 95% CI = 1.09-1.94, P < 0.001) and high des-γ-carboxyprothrombin (>40 mAU/mL, RR = 1.52, 95% CI = 1.13-2.02, P < 0.005) were significantly correlated with recurrence. AFP was selected as a significant factor even when the cut-off level was set lower (≤5 ng/mL). The risk of recurrence increased linearly according to the increase of the lowest AFP level after RFA and the adjusted ratios relative to AFP less than 5 ng/mL were 1.56, 2.14, 2.57 and 3.13 in AFP 5-10 ng/mL, 10-20 ng/mL, 20-50 ng/mL and over 50 ng/mL, respectively. In addition, the recurrence rate was predicted by the AFP level after RFA, regardless of the level before the treatment. Conclusion AFP less than 5 ng/mL after curative RFA was an important predictor of a better prognosis and was considered to indicate the low carcinogenic potential of the non-cancerous liver. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

39. Serum Glycan Markers for Evaluation of Disease Activity and Prediction of Clinical Course in Patients with Ulcerative Colitis.

Author

Miyahara, Koji, Nouso, Kazuhiro, Saito, Shunsuke, Hiraoka, Sakiko, Harada, Keita, Takahashi, Sakuma, Morimoto, Yuki, Kobayashi, Sayo, Ikeda, Fusao, Miyake, Yasuhiro, Shiraha, Hidenori, Takaki, Akinobu, Okada, Hiroyuki, Amano, Maho, Hirose, Kazuko, Nishimura, Shin-Ichiro, and Yamamoto, Kazuhide

Subjects
*BLOOD serum analysis, *GLYCANS, *BIOMARKERS, *ULCERATIVE colitis, *HOSPITAL admission & discharge, *COMPARATIVE studies, *PATIENTS
Abstract

Background: The aims of this study were to determine the change of whole-serum N-glycan profile in ulcerative colitis (UC) patients and to investigate its clinical utility. Methods: We collected serum from 75 UC patients at the time of admission and the same number of age/sex-matched healthy volunteers. Serum glycan profile was measured by comprehensive quantitative high-throughput glycome analysis and was compared with disease activity and prognosis. Results: Out of 61 glycans detected, 24 were differentially expressed in UC patients. Pathway analysis demonstrated that highly sialylated multi-branched glycans and agalactosyl bi-antennary glycans were elevated in UC patients; in addition, the glycan ratio m/z 2378/1914, which also increased in UC, showed the highest Area under Receiver Operating Characteristic curve (0.923) for the diagnosis of UC. Highly sialylated multi-branched glycans and the glycan ratio m/z 2378/1914 were higher in the patients with total colitis, Clinical Activity Index >10, Mayo endoscopic score 3, or a steroid-refractory status. In particular, the glycan ratio m/z 2378/1914 (above median) was an independent prognostic factor for the need for an operation (hazard ratio, 2.67; 95% confidence interval, 1.04–7.84). Conclusions: Whole-serum glycan profiles revealed that the glycan ratio m/z 2378/1914 and highly sialylated multi-branched glycans increase in UC patients, and are correlated with disease activity. The glycan ratio m/z 2378/1914 was an independent predictive factor of the prognosis of UC. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

41. Development of a new television set with personal computer...

Author

Miyahara, Koji and Inoue, Sadayuki

Subjects
*TELEVISION, *PERSONAL computers
Abstract

Presents a prototype of a novel television set (TV) with personal computer (PC) capability. Overview of the system; User interface of the television set; Functions of a mediator board; Conclusion.

Published
1997
Full Text
View/download PDF

43. Diagnostic Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Gastric Mesenchymal Tumors.

Author

Iwamuro, Masaya, Miyahara, Koji, Sakaguchi, Chihiro, Takenaka, Ryuta, Kobayashi, Sayo, Mouri, Hirokazu, Tanaka, Shigetomi, Toyokawa, Tatsuya, Tanaka, Shouichi, Nishimura, Mamoru, Yamauchi, Kenji, Tanaka, Takehiro, and Okada, Hiroyuki

Subjects
*POSITRON emission tomography, *GASTROINTESTINAL stromal tumors, *TUMORS, *LEIOMYOSARCOMA, *SMOOTH muscle tumors, *SCHWANNOMAS
Abstract

There have been no comparative studies investigating the results of 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients with gastric mesenchymal tumors, including leiomyomas, leiomyosarcomas, schwannomas, and gastrointestinal stromal tumors (GISTs). We retrospectively reviewed the data of 142 patients with pathologically diagnosed gastric mesenchymal tumors treated at 11 institutions. We analyzed the correlation between the maximum standardized uptake value (SUVmax) evaluated using fluorodeoxyglucose-positron emission tomography (FDG-PET) and the tumor size. The correlation between the SUVmax and mitotic index was also investigated in GISTs. The SUVmax (mean ± standard deviation) was 0.5 ± 0.6 in very low-risk GISTs (n = 42), 2.1 ± 0.7 in low-risk GISTs (n = 26), 4.9 ± 0.8 in intermediate-risk GISTs (n = 22), 12.3 ± 0.8 in high-risk GISTs (n = 20), 1.0 ± 1.0 in leiomyomas (n = 15), 6.9 ± 1.2 in schwannomas (n = 10), and 3.5 in a leiomyosarcoma (n = 1). The SUVmax of GISTs with an undetermined risk classification was 4.2 ± 1.3 (n = 8). Linear associations were observed between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax of GISTs with a high mitotic index was significantly higher than that of GISTs with a low mitotic index (9.6 ± 7.6 vs. 2.4 ± 4.2). In conclusion, we observed positive correlations between the SUVmax and tumor size in GISTs, leiomyomas, and schwannomas. The SUVmax also positively correlated with the mitotic index and risk grade in GISTs. Schwannomas showed a higher FDG uptake than GISTs and leiomyomas. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

48. Endoscopic Manifestations and Clinical Characteristics of Localized Gastric Light-Chain Amyloidosis.

Author

Iwamuro M, Tanaka S, Toyokawa T, Nishimura M, Tsuzuki T, Miyahara K, Negishi S, Ohya S, Tanaka T, and Otsuka M

Subjects
Male, Female, Humans, Retrospective Studies, Immunoglobulin Light-chain Amyloidosis diagnosis, Amyloidosis diagnosis, Amyloidosis pathology, Stomach Diseases diagnosis, Stomach Diseases pathology
Abstract

To determine the endoscopic and clinical features of localized gastric amyloid light-chain (AL) amyloidosis, we retrospectively examined the characteristics of nine patients (eight men and one woman) encountered by the hospitals in our network. Lesions were predominantly flat and depressed with surface vascular dilatation (n=5); others were characterized by subepithelial lesions (n=2), mucosal color change (n=1), and a mass-like morphology with swollen mucosal folds (n=1). Colonoscopy (n=7), video capsule enteroscopy (n=2), serum (n=5) and urine immunoelectrophoresis (n=4), and bone marrow examination (n=3) were performed to exclude involvement of organs other than the stomach. As treatment for gastric lesions of AL amyloidosis, one patient each underwent endoscopic submucosal dissection (n=1) and argon plasma coagulation (n=1), while the remaining seven patients underwent no specific treatment. During a mean follow-up of 4.2 years, one patient died 3.2 years after diagnosis, but the cause of death, which occurred in another hospital, was unknown. The remaining eight patients were alive at the last visit. In conclusion, although localized gastric AL amyloidosis can show various macroscopic features on esophagogastroduodenoscopy, flat, depressed lesions with vascular dilatation on the surface are predominant., Competing Interests: No potential conflict of interest relevant to this article was reported.

Published
2023
Full Text
View/download PDF

49. Clinicopathological Characteristics of Superficial Barrett's Adenocarcinoma in a Japanese Population: A Retrospective, Multicenter Study.

Author

Hamada K, Kanzaki H, Miyahara K, Nakagawa M, Mouri H, Mizuno M, Takahashi S, Hori S, Nasu J, Tsuzuki T, Miyaike J, Takenaka R, Yamauchi K, Kobayashi S, Toyokawa T, Inoue M, Nishimura M, Matsubara M, Tomoda J, Yamasaki Y, Tanaka T, Shirakawa Y, Kawahara Y, Fujiwara T, and Okada H

Subjects
Humans, Japan epidemiology, Retrospective Studies, Adenocarcinoma epidemiology, Adenocarcinoma etiology, Adenocarcinoma surgery, Barrett Esophagus epidemiology, Barrett Esophagus pathology, Esophageal Neoplasms epidemiology, Esophageal Neoplasms etiology, Esophageal Neoplasms surgery
Abstract

Objective Although Barrett's adenocarcinoma (BA) remains a minor disease in Japan, its incidence has been gradually increasing. We analyzed the characteristics of BA in Japanese populations. Methods We retrospectively reviewed medical records and analyzed the clinicopathological differences between short-segment Barrett's esophagus (SSBE) and long-segment Barrett's esophagus (LSBE), as well as metastasis. Local recurrence and metachronous lesions were analyzed only in patients who underwent endoscopic resection (ER). Patients Consecutive patients who had pathological T1 BAs resected by ER or surgery from January 2003 to December 2017. Results A total of 168 patients were analyzed, including 139 with SSBE and 29 with LSBE. In total, 67% of the SSBE lesions and 32% of the LSBE lesions were located between 0 and 3 o'clock (p=0.0014). No patients who achieved pathological margin-free resection (pR0) and 17% of patients who did not achieve pR0 experienced local recurrence (p=0.0131). None of the patients without lymphovascular involvement, a poorly differentiated component, lesion size of >30 mm, and submucosal invasion of >500 μm experienced metastasis. The 5-year cumulative incidence rate of metachronous BA after ER was 0% in patients with SSBE and 40% in patients with LSBE (p=0.0005). Conclusion Superficial BA was likely to be detected at the right anterior wall of SSBE in the Japanese population. The risk for metachronous BA after ER was high in Japanese patients with LSBE, as in Western patients.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results